nefazodone sold formerly brand names serzone dutonin nefadar among others atypical antidepressant medication used treatment depression nefazodone still available united withdrawn countries due rare liver toxicity medication taken side effects nefazodone include dry mouth sleepiness nausea dizziness blurred vision weakness lightheadedness confusion postural low blood pressure among rarely nefazodone cause serious liver damage incidence death liver transplantation every patient nefazodone phenylpiperazine compound related trazodone described serotonin antagonist reuptake inhibitor sari due combined actions potent antagonist serotonin receptors weak reuptake inhibitor sndri nefazodone introduced medical use generic versions introduced serious liver toxicity first reported nefazodone withdrawn markets however continues available united states generic one manufacturer teva nefazodone used treat major depressive disorder aggressive behavior panic nefazodone available mg mg mg mg mg tablets oral contraindications include coadministration terfenadine astemizole cisapride pimozide carbamazepine nefazodone contraindicated patients withdrawn nefazodone evident liver injury well shown hypersensitivity drug inactive ingredients phenylpiperazine antidepressants furthermore coadministration triazolam nefazodone avoided patients including elderly since causes significant increase plasma level triazolam commercially available dosage forms triazolam permit sufficient dosage reduction coadministrated reduction initial dosage triazolam common mild side effects nefazodone reported clinical trials often placebo include dry mouth sleepiness nausea dizziness blurred vision weakness lightheadedness confusion orthostatic hypotension rare serious adverse reactions may include allergic reactions fainting painfulprolonged erection nefazodone especially associated increased appetite weight also known low levels sexual side effects comparisons nefazodone cause severe liver damage damage may lead need liver transplantation death incidence severe liver damage approximately every time started withdrawn market nefazodone associated least cases liver injury death led death united cases liver toxicity two led transplantation canadian study cases noted databases like used study tended include small proportion suspected drug treatment protocols suggest screening preexisting liver disease initiating nefazodone known liver disease prescribed nefazodone serum ast serum alt levels times upper limit normal uln treatment permanently withdrawn regular enzyme labs done every six months nefazodone firstline nefazodone potent inhibitor may interact adversely many commonly used medications metabolized nefazodone acts primarily potent antagonist serotonin receptor lesser extent serotonin also high affinity receptor serotonin receptor relatively lower affinity receptor dopamine nefazodone low significant affinity serotonin norepinephrine dopamine transporters well therefore acts weak serotoninnorepinephrinedopamine reuptake inhibitor low potentially significant affinity histamine receptor antagonist hence may antihistamine nefazodone negligible activity muscarinic acetylcholine receptors accordingly anticholinergic bioavailability nefazodone low variable plasma protein binding approximately bound nefazodone metabolized liver main enzyme involved thought drug least four active metabolites include hydroxynefazodone parahydroxynefazodone triazoledione nefazodone short elimination halflife metabolite hydroxynefazodone similarly elimination halflife hours whereas elimination halflives triazoledione mcpp longer around hours hours due long elimination halflife triazoledione major metabolite predominates circulation nefazodone treatment plasma levels times higher nefazodone conversely hydroxynefazodone levels nefazodone steady plasma levels mcpp low nefazodone hence mcpp minor mcpp thought formed nefazodone specifically ratios braintoplasma concentrations mcpp nefazodone mice rats suggesting brain exposure mcpp may much higher plasma conversely hydroxynefazodone levels brain plasma spite relatively low plasma concentrations brain exposure mcpp may substantial whereas hydroxynefazodone may nefazodone alphaphenoxyl derivative etoperidone turn derivative nefazodone discovered scientists bristolmyers squibb bms seeking improve trazodone reducing sedating bms obtained marketing approvals nefazodone worldwide including united states europe marketed united states brand name europe brand name first reports serious liver toxicity nefazodone published instances quickly followed many additional fda obligated bms add black box warning potential fatal liver toxicity drug worldwide sales public citizen filed citizen petition asking fda withdraw marketing authorization united states early organization sued fda attempt force withdrawal fda issued response petition june filed motion dismiss public citizen withdrew sales nefazodone million time also marketed additional brand names serzonil nefadar generic versions introduced united states health canada withdrew marketing authorization april bms announced going discontinue sale serzone united states june said due declining sales generic versions available united time bms already withdrawn drug market europe australia new zealand august teva pharmaceuticals placed nefazodone shortage due shortage raw ingredient december nefazodone made available nefazodone generic name drug inntooltip international nonproprietary name bantooltip british approved name néfazodone dcftooltip dénomination commune française nefazodone hydrochloride usantooltip united states adopted name usptooltip united states nefazodone marketed number brand names including dutonin attooltip austria estooltip spain ietooltip ireland uktooltip united kingdom menfazona estooltip spain nefadar chtooltip switzerland detooltip germany notooltip norway setooltip sweden nefazodone bms attooltip austria nefazodone hydrochloride teva ustooltip united states reseril ittooltip italy rulivan estooltip spain serzone autooltip australia catooltip canada ustooltip united nefazodone development treatment panic disorder reached phase clinical trials indication development discontinued use nefazodone prevent migraine studied due antagonism serotonin httpsenwikipediaorgwikinefazodone